Compass Therapeutics (CMPX) Non-Current Debt (2019 - 2020)
Compass Therapeutics recorded quarterly Non-Current Debt of $1.9 million in Q4 2020, down 49.95% quarter-over-quarter from $3.7 million in Q3 2020, and down 79.91% year-over-year from $9.3 million in Q1 2020.
Compass Therapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $1.9 million for Q4 2020.
- In Q4 2020, Non-Current Debt fell 79.91% year-over-year to $1.9 million; the TTM figure through Dec 2020 stood at $1.9 million (down 79.91% YoY), while the FY2020 annual figure was $1.9 million, down 79.91% from the prior year.
- Non-Current Debt came in at $1.9 million for Q4 2020 at Compass Therapeutics, down from $3.7 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $9.3 million in Q4 2019 to a low of $1.9 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.87 Mn |
| Dec 31, 2020 | 1.87 Mn |
| Sep 30, 2020 | 3.73 Mn |
| Sep 30, 2020 | 3.73 Mn |
| Jun 30, 2020 | 5.59 Mn |
| Jun 30, 2020 | 5.59 Mn |
| Dec 31, 2019 | 9.29 Mn |
| Dec 31, 2019 | 9.29 Mn |